Stratasys and collplant unite technologies to transform healthcare with industrial-scale bioprinting of tissues and organs

Eden prairie, minn. & rehovot, israel--(business wire)---- $ssys #3dprinting--stratasys ltd. (nasdaq: ssys) and collplant biotechnologies (nasdaq: clgn) today announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using stratasys' p3 technology-based bioprinter and collplant's rh-collagen-based bioinks.
CLGN Ratings Summary
CLGN Quant Ranking